Brielle Benyon

Articles

FDA Approves Frontline Pembrolizumab for HER2+ Gastric, GEJ Cancer

May 05, 2021

The FDA granted an accelerated approval to pembrolizumab plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.